王建功,王晓红,杨俊泉,李国欢,胡万宁
WANG Jiangong,WANG Xiaohong,YANG Junquan,LI Guohuan,HU Wanning

• 1:唐山市肿瘤医院生物治疗科
• 2:唐山市肿瘤医院放化疗科

摘要(Abstract)：

目的:探讨重组人p53腺病毒(rAd-p53)基因联合放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:64例Ⅲ期NSCLC患者,随机分为A组31例(rAd-p53+放化疗),B组33例(放化疗);A组采用3支rAd-p53用10 mL生理盐水稀释,缓慢进行支气管动脉灌注,共灌注2次;3 d后,A、B组同步放化疗,放疗为60Gy/30F;化疗采用PE化疗方案,第1、8、29、36天给顺铂50 mg/m2,,第1~5、29~33天给足叶已甙50 mg/m2。结果:A组、B组有效率分别为70.97%和45.45%,两组比较差异有统计学意义(P<0.05);A组患者1年生存率、放射性肺炎、放射性食管炎发生率分别为74.19%(23/31)、41.94%(13/31)、67.74%(21/31);B组患者1年生存率、放射性肺炎、放射性食管炎发生率分别为69.70%(23/33)、39.39%(13/33)、69.70%(23/33),两组比较差异均无统计学意义(P>0.05)。结论:重组人p53腺病毒联合放化疗提高了局部晚期NSCLC的近期疗效,且未增加放射性肺炎及放射性食管炎发生率。
Objective: To explore the curative efficacy and safety of recombinant human adenovirus( rAd-p53) combined with radiochemotherapy in treating local advanced non-small cell lung cancer( NSCLC). Methods: Sixty four cases with local advanced NSCLC were randomly divided into. rAdp53 combined with radiochemotherapy treating group( group A),radiochemotherapy group( group B). Group A: three rAd-p53 were diluted with 10 mL normal saline and slowly infused to bronchial artery for 2 times. In the three days after infusion,the two groups were accepted radiochemotherapy. Radiotherapy programs: 60 Gy /30f. Chemotherapy programs: PE method,giving 50 mg / m2cisplatin on the 1st,8th,29th,36th days and 50 mg/m2etoposide from the 1stday to the 5thday and from the 29thto the 33thday. Results: The effective rates were 70. 97% and 45. 45% in group A and B respectively( P < 0. 05). The survival rates in one year,the occurrences of radiation pneumonitis and radiation esophagitis were 74. 19 %( 23 /31),41. 94 %( 13 /31) and 67. 74%( 21 /31) respectively in group A and were 69. 70 %( 23 /33),39. 39 %( 13 /33),69. 70 %( 23 /33) in group B,there were not statistical differences between the two groups( P > 0. 05). Conclusions: rAd-p53 combined with radiochemotherapy can improve the short-term effects in treating local advanced NSCLC with out increasing adding radiation pneumonitis and radiation esophagitis rates.

关键词(KeyWords)： 癌,非小细胞肺;重组人p53腺病毒;化疗;放射疗法;基因治疗
carcinoma,non-small-cell cancer;recombinant human p53 adenovirus;radiotherapy;chemotherapy;gene therapy

Abstract:

Keywords:

基金项目(Foundation): 河北省卫生厅医学科学研究重点课题计划资助项目(2011-0196)

作者(Author): 王建功,王晓红,杨俊泉,李国欢,胡万宁
WANG Jiangong,WANG Xiaohong,YANG Junquan,LI Guohuan,HU Wanning

DOI: 10.19367/j.cnki.1000-2707.2014.02.024

参考文献(References)：

• [1]胡智刚.回生口服液联合放疗治疗术后NSCLC疗效观察[J].今日药学,2013(9):600-603.
• [2]Curran WJ,Paulus R,Langer CJ,et al.Sequential vs.concurrent chemoradiation for stage III non-small cell lung cancer:randomized phase III trial RTOG9410[J].J Natl Cancer Inst,2011(19):1452-1460.
• [3]董磊.基因治疗联合化疗治疗肺癌胸腔积液临床观察[J].临床肺科杂志,2013(8):1481-1482.
• [4]Eisenhauer EA,Therasse P,Bogaerts J,et a1.New response evaluation criterion in solid tumors:revised RECIST guideline(version1.1)[J].Eur J Can,2009(2):228-247.
• [5]MiLLer AB,Hoogstraten B,Staquet M,et a1.Reporting results of cancer treatment[J].Cancer,1981(1):207-214.
• [6]Govaert SL,Troost EG,Schuurbiers OC,et al.Treatment outcome and toxicity of intensity-modulated(chemo)radiotherapy in stage III non-small cell lung cancer patients[J].Radiat Oncol,2012(7):150.
• [7]Bhandari V1,Gupta KL,Taran R.A comparison of results by sequential and concurrent chemo radiotherapy in locally advanced carcinoma esophagus[J].Indian J Cancer,2013(4):341-344.
• [8]Auperin A,Le Pechoux C,Rolland E,et al.Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J].J Clin Oncol 2010(13):2181-2190.
• [9]Gao W,Keohavong P.Detection of Point Mutations of Kras Oncogene and p53 Tumor-Suppressor Gene in Sputum Samples[J].Methods Mol Biol,2014(1105):325-344.
• [10]Huh JW,Kim HC,Kim SH,et al.Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer:Predictive role of lymph node metastasis and survival[EB/OL].J Surg Oncol,2014(13)[2014-03-13]http://onlinelibrary.wiley.com/doi/10.1002/jso.23592/abstract;jsessionid=2EA3A5C785E1076D905E8B287163679F.f03t03.
• [11]Beckta JM1,Ahmad SF1,Yang H,et a1.Revisiting p53 for cancer-specific chemo-and radiotherapy:Ten years after[EB/OL].Cell Cycle,2014(5)[2014-03-01]https://www.landesbioscience.com/journals/cc/article/28108/
• [12]张汉群,倪婷婷,鲁亮,等.放化疗同步治疗局部晚期鼻咽癌的临床观察[J].贵阳医学院学报,2011(1):81-84.
• [13]马文群.手术切除联合术后间质内放化疗治疗脑恶性胶质瘤[J].贵阳医学院学报,2012(3):304-305.
• [14]蔡仙丽.P53基因在宫颈癌组织中的表达及与细胞质胸苷激酶关系的临床研究[J].中华危重症医学杂志,2013(4):35-37.
• [15]Horio Y,Hasegawa Y,Sekido Y,eta1.Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-Small cell lung cancer cells[J].Cancer Gen Ther,2000(4):537-544.
• [16]Kawabe S,Munshi A,Zumstein LA,et al.Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts[J].Int J Radiat Biol,2001(2):185-194.
• [17]Nemunaitis J,Meyers T,Senzer N,et a1.Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer[J].Mol Ther,2006(6):1185-1191.
• [18]任骅,王绿化,王小震,等.不同化疗方案对局部晚期非小细胞肺癌同步放化疗疗效的影响[J].中华肿瘤杂志,2009(2):143-147.

文章评论(Comment)：